- Conditions
- KRAS Gene Mutation
- Interventions
- TVB-2640
- Drug
- Lead sponsor
- David E Gerber
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 817–840
of 3,556
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- ILX651
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Santa Monica, California • Aurora, Colorado + 7 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- SID530, Taxotere
- Drug
- Lead sponsor
- SK Chemicals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Miami, Florida • Canton, Ohio
- Conditions
- Lung Cancer
- Interventions
- tipifarnib
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 3
- States / cities
- Jacksonville, Florida • Chicago, Illinois • Rochester, Minnesota
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Azacitidine, Docetaxel, Entinostat, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 1 more
- Conditions
- Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Fatigue, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer
- Interventions
- escitalopram oxalate, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Lung Cancer, Non-Small Cell
- Interventions
- Dostarlimab, Belrestotug, Pembrolizumab, Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Ocala, Florida • Honolulu, Hawaii • Lexington, Kentucky + 4 more
- Conditions
- Lung Cancer
- Interventions
- Ibrutinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- ABBV-155, Paclitaxel, Docetaxel
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • Orange, California + 17 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Biodesix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,006 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 42
- States / cities
- Huntsville, Alabama • Tuscaloosa, Alabama • Fayetteville, Arkansas + 38 more
- Conditions
- Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma, NSCLC Non-small Cell Lung Cancer, Squamous Cell Cancer of the Head and Neck, UC (Urothelial Cancer), MSI-H Cancer
- Interventions
- Decoy20, Tislelizumab
- Drug
- Lead sponsor
- Indaptus Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 8 more
- Conditions
- Lung Neoplasms
- Interventions
- CP-547,632
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 20
- States / cities
- Greenbrae, California • San Mateo, California • San Pablo, California + 13 more
- Conditions
- Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer)
- Interventions
- Bright Light Therapy
- Device
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Hypofractionated Stereotactic Boost, Carboplatin, Paclitaxel, Image-guided IMRT
- Radiation · Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- ABI-007
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Gefitinib, Docetaxel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 32 more
- Conditions
- Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, EGFR Exon 20 Mutation, EGFR Exon 20 Insertion Mutation, EGFR Activating Mutation, Antineoplastic Agents, Metastatic Lung Cancer, Brain Metastases, EGFR-mutated NSCLC, EGFR Atypical Mutations, Including G719X and L861Q
- Interventions
- BLU-451, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Blueprint Medicines Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 13
- States / cities
- Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more
- Conditions
- HER2-expressing Cancers
- Interventions
- ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 6 more
- Conditions
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Interventions
- PF-07248144, Fulvestrant, Letrozole, Palbociclib, PF-07220060, PF-07850327, ARV-471, vepdegestrant
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 23
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Non-small Cell Lung Cancer, Bladder Cancer
- Interventions
- CVA21/pembrolizumab
- Biological
- Lead sponsor
- Viralytics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 9
- States / cities
- Santa Monica, California • Coral Gables, Florida • Niles, Illinois + 6 more
- Conditions
- Lung Cancer
- Interventions
- cetuximab
- Biological
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 157
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 107 more
- Conditions
- Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
- Interventions
- Nivolumab, Relatlimab, Carboplatin, Cisplatin, Paclitaxel, Nab-Paclitaxel, Pemetrexed
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 29
- States / cities
- Duarte, California • Orange, California • New Haven, Connecticut + 25 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
- Interventions
- LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 87
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more
- Conditions
- Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Squamous Non-small-cell Lung Cancer, Large Cell Carcinoma Lung, Adenocarcinoma Lung
- Interventions
- IMU-201 (administered as PD1-Vaxx) - Regimen 1, IMU-201 (administered as PD1-Vaxx) - Regimen 2, IMU-201 (administered as PD1-Vaxx) - Regimen 3, Atezolizumab, Standard of care chemotherapy
- Biological · Drug
- Lead sponsor
- Imugene Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Hackensack, New Jersey • Columbus, Ohio